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Traditional medicines that stimulate or modulate the immune system can be used as
innovative approaches to treat immunological diseases. The herbal medicine IMOD has
been shown to strongly modulate immune responses in several animal studies as well
as in clinical trials. However, little is known about the mechanisms of IMOD to modulate
immunity. Here we have investigated whether IMOD modulates the immunological
function of human dendritic cells (DCs). IMOD alone did not induce DC maturation nor
production of cytokines. Notably, IMOD decreased the production of pro-inflammatory
cytokines IL-6, IL-12 p70, and TNFα by LPS-activated DCs at both mRNA and protein
levels in a dose dependent manner. In contrast, treatment with IMOD did not affect
LPS induced-production of the anti-inflammatory cytokine IL-10. Furthermore, IMOD
inhibited T cell activation/proliferation by LPS-treated DCs and skewed T-cells responses
toward the T helper type 2 polarization. These data strongly indicate that IMOD has a
potent immunomodulatory ability that affects TLR signaling and thereby modulates DC
function. Insight into the immunomodulatory effect of herbal medicine IMOD may provide
innovative strategies to affect the immune system and to help combat various diseases.
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Introduction
Elucidation of the mechanisms of action of herbal medicines is important to understand their
therapeutic eﬀects on diﬀerent diseases and to design successful therapies (Huang et al., 2008).
Recently, a new herbal based medicine with immunomodulatory capacities – Setarud (IMOD) –
was introduced as an additional therapy in various inﬂammatory diseases and HIV infection
(Mohraz et al., 2009; Mahmoodpoor et al., 2010). IMOD has been shown to aﬀect immune
responses in animal studies (Mohammadirad et al., 2011). IMOD consists of a mixture of
herbal extracts (Tanacetum vulgare, Rosa canina, and Urtica dioica) supplemented with sele-
nium. The diﬀerent herbal ingredients of IMOD possess anti-inﬂammatory, anti-viral and immune
modulating properties; the lectin and polysaccharide fractions of U. dioica (nettle) exhibits
anti-viral and anti-inﬂammatory properties (Balzarini et al., 1992; Chrubasik et al., 2007a,b),
whereas the extract from T. vulgare possesses anti-inﬂammatory properties (Schinella et al.,
1998). Beta-caroten of R. canina fruits delays the increase of serum blood glucose and cholesterol
(Ninomiya et al., 2007). Selenium is an essential trace element that plays a key role in protecting
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cells from oxidative stress, and selenium supplementation in the
diet may reduce the risk of cardiomyopathy, cancer, and immune
disorders in humans (Rayman, 2000; Ren et al., 2012).
IMOD treatment positively inﬂuences the treatment of
patients with severe sepsis by decreasing the levels of tumor
necrosis factor (TNF) in their serum (Mahmoodpoor et al., 2010).
Additionally, IMOD has also been found to be eﬀective in other
types of immune inﬂammatory-based diseases such as ulcera-
tive colitis and type I diabetes (Mohammadirad et al., 2011).
Furthermore, IMOD has a positive inﬂuence on the CD4 level
in HIV infected individuals (Mohraz et al., 2009, 2013). These
preclinical and clinical studies suggest that IMOD limits inﬂam-
matory responses but the mechanisms of immunodulation by
IMOD remain unknown.
Dendritic cells (DCs) are essential to initiate adaptive immune
responses to diﬀerent pathogens such as bacteria, viruses, and
fungi (Banchereau and Steinman, 1998). DCs sample the envi-
ronment for invading pathogens and interactions with pathogens
or pathogenic components leads to DC maturation and conse-
quently migration to the lymphoid tissues, where mature DCs
present processed antigens on MHC class II and I molecules
to CD4+ and CD8+ T cells, respectively, thereby activating
pathogen-speciﬁc T cells. Furthermore, DCs are crucial in
instructing CD4+ T helper (TH) cell polarization, which is
paramount to an eﬃcient immune response (Kapsenberg, 2003).
TH polarization is driven by secretion of speciﬁc cytokines and
cell-surface expression of co-stimulatory molecules by DCs in
response to infectious pathogens. The pro-inﬂammatory cytokine
IL-12 promotes the development of TH1, which secrete IFN-
γ and are paramount in the protection against intracellular
microorganisms. In contrast a suppression of IL-12 and induction
of cytokines such as IL-10 and IL-4 promotes TH2 development
(Pulendran et al., 2010). TH2 cells secrete mainly IL-4 to induce
humoral immunity against extracellular pathogens (Chen et al.,
2012).
Here, we have investigated the eﬀect of IMOD on DC func-
tion and subsequent TH cell polarization. IMOD alone did not
aﬀect DC function but our data strongly indicate that IMOD
suppressed TLR4-induced pro-inﬂammatory cytokine produc-
tion by DCs. Interestingly, IMOD did not aﬀect expression of
anti-inﬂammatory cytokine IL-10. Concomitantly, we observed
that IMOD suppressed T cell activation and skewed TH cell
polarization toward TH2. These data strongly suggest that IMOD
decreases DC activation via TLRs, which might explain its
immunomodulatory eﬀects in inﬂammatory diseases. Further
research into the exact molecular mechanism of TLR suppression
might provide novel targets for immunomodulatory therapies.
Materials and Methods
Cell Culture and Dendritic Cell Stimulation
Immature DCs were generated from monocytes obtained from
buﬀy coats of healthy blood donors (Sanquin Bloedbank,
Amsterdam, The Netherlands) after culture in presence of IL-
4 and GM-CSF for 6 days as described before (Geijtenbeek
et al., 2003). The study was approved by the local Medical Ethics
Review Committee in accordance with the ethical guidelines
of the Academic Medical Center, and Declaration of Helsinki.
100,000 DCs were stimulated with diﬀerent concentrations
of IMOD (1:400, 1:800, 1:1600, 1:3200; stock concentration
30 mg/mL, Pars Roos Co., Teheran, Iran) in the presence or
absence of Escherichia coli LPS (10 ng/ml, Sigma-Aldrich). For
isolation of mRNA, cells were lysed after 6 h of incubation.
To measure cytokine production and expression of cell sur-
face markers, cells were incubated for 18 h. IL-6, IL-12p40,
IL-10, and TNF-α were measured in culture supernatants by
ELISA (Invitrogen) according to the manufacturer’s recom-
mendations DCs were analyzed by ﬂow cytometry analysis
(FACS) for expression of CD80, and CD86 (CD80-PE, CD86-PE,
Pharmingen).
RNA Extraction, and Quantitative Real-Time
PCR
mRNA was speciﬁcally isolated with the mRNA capture kit
(Roche) and cDNAwas synthesized with the reverse transcriptase
kit (Promega). For real-time PCR analysis, PCR ampliﬁcation was
performed in the presence of SYBR green, as previously described
(García-Vallejo et al., 2004). Speciﬁc primers were designed using
Primer Express 2.0 (Applied Biosystems, Table S1; Gringhuis
et al., 2007). The Ct value is deﬁned as the number of PCR
cycles where ﬂuorescence signal exceeds the detection thresh-
old value. For each sample, the normalized amount of target
mRNA Nt was calculated from the obtained Ct values for both
target and GAPDH mRNA with Nt = 2Ct(GAPDH) − Ct(target) .
The relative mRNA expression was obtained by setting Nt in
LPS-stimulated DCs at 1 within one experiment and for each
donor.
T Lymphocyte Proliferation (Mixed
Lymphocyte Reaction)
Dendritic cells were pre-incubated with IMOD (concentration
1:800) for 18 h in presence and absence of LPS. Thereafter
the DCs were washed to remove remaining IMOD before
adding of allogeneic T cells. DCs were cultured with allo-
geneic peripheral blood lymphocytes (PBL; 1 × 105) at dif-
ferent ratios (1: 50 to 1: 400) for 5 days. T cells proliferation
was assessed by measuring the overnight incorporation of BrdU
(BrdU labeling reagent, Invitrogen. PE mouse anti BrdU Ab, BD
Pharmingen).
T Cell Differentiation Assay
Highly puriﬁed CD4+CD45RA+CD45RO− naive Th cells
(>98% as assessed by ﬂow cytometry) were puriﬁed from PBMCs
using a human CD4+/CD45RO− column kit (R&D Systems,
Minneapolis, MN, USA). Immature DCs were stimulated with
diﬀerent concentrations of IMOD (1: 800 and 1: 1600) for 48 h.
DCs were washed extensively, and naive CD4+ T cells were added
to stimulated DCs. On days 6 and 9 of co-culture, cells were
stimulated with IL-2 (10 U/ml). On day 13, T cells were restim-
ulated with the phorbol ester PMA (100 ng/ml) and ionomycin
(1 μg/ml) in the presence of brefeldin A (10 μg/ml), stained for
intracellular IL-4 and IFN-γ with phycoerythrin- and ﬂuorescein
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isothiocyanate–labeled antibodies (Becton Dickinson), respec-
tively, and analyzed on a FACSCanto (Becton Dickinson).
Statistics
Statistical analysis was performed using the Student’s t-test
for paired observations, unless stated otherwise. Comparisons
with probability values of less than 0.05 were considered to be
signiﬁcant.
Results
IMOD has no Significant Influence on DC
Maturation
First we investigated the eﬀect of IMOD on DC function.
Human monocyte-derived DCs were incubated with diﬀer-
ent concentrations of IMOD for 18 h and DC maturation
was determined by measuring expression of co-stimulatory
molecules CD80 and CD86. Concentrations were chosen that
did not aﬀect cell viability (Figure S1). IMOD alone did
not induce DC maturation, as expression of both matu-
ration markers, CD80 and CD86, on IMOD-treated DCs
was similar to that of immature DCs (Figures 1A,C and
Figure S2). Next, we investigated whether IMOD aﬀects DC
maturation induced by TLR4 ligand LPS. IMOD treatment did
not aﬀect the LPS-induced expression of maturation mark-
ers CD80 and CD86. CD86 expression was decreased only at
the highest IMOD concentration (Figures 1B,D and Figure
S2). Additionally the levels of other maturation markers such
as CD83, CD40, or HLA-DR were not aﬀected by IMOD
treatment, in either unstimulated or LPS treated cells (Figure




Next, we investigated whether IMOD induces cytokine pro-
duction or aﬀects LPS-induced cytokine production. Immature
DCs were stimulated with diﬀerent concentration of IMOD
in the presence or absence of LPS, and cytokines were mea-
sured by real time quantitative PCR. Treatment of imma-
ture DCs with IMOD alone did not induce cytokines (data
not shown). Notably, IMOD inhibited LPS-induced produc-
tion of pro-inﬂammatory cytokines IL-6, IL-12p35, IL12p40,
and TNFα at mRNA level, in a dose dependent manner
(Figures 2A,C,E,F). Consequently the levels of LPS induced
IL6 and IL12p70 were also abolished by IMOD in dose depen-
dent manner (Figures 2B,G). LPS-induced TNF secretion was
already strongly inhibited by the lowest IMOD concentration,
which may suggest additional regulation by IMOD at the level
FIGURE 1 | IMOD treatment does not affect dendritic cell (DC) maturation.
Immature DCs were stimulated with different dilutions of IMOD in the presence
or absence of LPS. 18 h after stimulation, expression of maturation markers
CD80 (A,B) and CD86 (C,D) was measured by flow cytometry. The data are
presented as mean ± standard deviation from at least three independent
experiments. ∗P < 0.05. IMOD/LPS-treated vs. LPS stimulated samples.
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of translation or protein stability (Figure 2D). In contrast the
anti-inﬂammatory cytokine IL-10 mRNA levels induced by LPS
treatment were not aﬀected (Figure 3A), while there was par-
tial reduction of LPS-induced IL10 secretion caused by the
highest IMOD concentration (Figure 3B). These data suggest
that IMOD might aﬀect translation rate but not transcription
of il10. Taken together those data suggest that speciﬁcally
IMOD suppresses pro-inﬂammatory cytokines induced by
LPS.
IMOD Attenuates DC-Induced T Cell
Activation
Activation of T lymphocyte by mature DCs is crucial to ini-
tiate an eﬀective adaptive immune response against invading
pathogens. Therefore, we investigated whether IMOD interfered
with the T cell activation capacity of DCs. Our results show
that IMOD treatment had a negative inﬂuence on T cell pro-
liferation induced by LPS-stimulated DCs (Figure 4). Although
the diﬀerences did not reach statistical signiﬁcance, there was a
FIGURE 2 | 1IMOD suppresses TLR4-induced pro-inflammatory
cytokines. Immature DCs were stimulated with LPS alone or in combination
with IMOD and cytokine expression was measured after 6 and 18 h at mRNA
and protein levels, respectively. IMOD suppressed mRNA levels of LPS-induced
IL-6 (A), TNFα (C), IL-12p35 (E), and IL12p40 (G) as measured by quantitative
real time PCR. Similarly, IMOD inhibited cytokine production of IL-6 (B), TNFα
(D), and IL-12p70 (F) at protein level as measured by ELISA. The data are
represented as mean ± standard deviation of at least three independent
experiments. ∗P < 0.05; ∗∗P < 0.01. IMOD/LPS-treated vs. LPS stimulated
samples.
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FIGURE 3 | IMOD does not affect IL-10 expression by LPS-stimulated
dendritic cells. DCs were stimulated with LPS alone or in combination with
IMOD and IL-10 expression was measured after 6 and 18 h at mRNA (A) and
protein level (B), respectively. The data are represented as mean ± standard
deviation of at least three independent experiments. ∗P < 0.05 IMOD/LPS
treated vs. LPS stimulated samples.
clear trend toward lower T cell proliferation rate when stimu-
lated with DCs activated in the presence of IMOD. IMOD alone
did not inﬂuence T cell proliferation induced by immature DCs
(Figure 4). Additionally, IMOD alone did not induce T cell pro-
liferation or had an eﬀect on PHA/IL2 induced proliferation
(Figure S3). These data may suggest that IMOD has a potential
to suppresses T cell activation capacity of LPS-activated DC.
IMOD Treatment Skews T Helper Cell
Polarization Toward Promotes TH2
IL-12p70 expression is necessary for TH1 diﬀerentiation, as
inhibition of IL-12p70 skews T cells responses toward TH2
cytokines proﬁle. Because IMOD inhibited production of pro-
inﬂammatory cytokines including IL-12p70, we investigated
whether IMOD modulated T helper cell polarization. DCs were
stimulated with diﬀerent concentrations of IMOD in presence or
absence of LPS. Subsequently, DCs were washed and mixed with
naïve CD4+ T cells and T cell polarization was investigated. Our
results show that IMOD-stimulatedDCs skewed T cells responses
FIGURE 4 | IMOD inhibits DC-induced T cell proliferation. Immature
dendritic cells were stimulated with IMOD (concentration 1:800) in the
presence and absence of LPS. After 18 h of incubation DCs were washed
and cultured with allogenic PBLs (1 × 105) at different ratios for 5 days. The
proliferation of T lymphocytes was assessed by overnight BrdU incorporation.
The results are representative of independent experiments obtained from
three donors.
toward the TH2 cytokines proﬁle (Figure 5A). Stimulation of
DCs with LPS induced a mixed TH1/TH2 response, whereas co-
treatment with IMOD suppressed induction of TH1 cells leading
to more TH2 skewed response (Figure 5B). These data strongly
suggest that IMOD skews T helper cell polarization toward TH2.
Discussion
Herbal extracts have been shown to modulate immune responses
during inﬂammation (Balzarini et al., 1992; Huang et al., 2008;
Alvarez et al., 2011). Setarud (IMOD) is a natural medicine that
consists of a mixture of herbal extracts including U. dioica (net-
tle), T. vulgare (Tansy), and R. canina with addition of selenium,
ﬂavonoids, and carotenes (Mohammadirad et al., 2011). The
ﬂavonoid compounds extracted from the T. vulgare leaf showed
immunomodulatory activity (Xie et al., 2007). The ethyl acetate
extract of aerial parts of T. vulgare and the isolated compound
parthenolide possess strong anti-HSV1 activity (Alvarez et al.,
2011). Furthermore, R. canina exhibits anti-oxidative and anti-
inﬂammatory properties (Lattanzio et al., 2011) and its extract has
been employed successfully in the number of studies in patients
suﬀering from rheumatoid arthritis, osteoarthritis, and low back
pain (Chrubasik et al., 2008). Until now IMODhas been shown to
have beneﬁcial eﬀects in patients with severe sepsis, by lowering
the levels of TNFα when compared with patients receiving only
standard treatment (Mahmoodpoor et al., 2010). Furthermore,
IMOD has been shown to increase CD4+ T cell counts in HIV
infected patients (Mohraz et al., 2009, 2013). Thus, IMOD has
been shown to modulate immune responses during diﬀerent
inﬂammatory disorders (Farhoudi et al., 2013) but little is known
about the molecular mechanism of IMOD. Our data suggest that
IMODmodulates DC function.
IMOD alone did not induce DC maturation but it strongly
inhibited LPS-induced pro-inﬂammatory cytokines IL-6, TNFα,
and IL-12p70. The inhibition of pro-inﬂammatory cytokines
might prevent over activation of the immune system, which
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FIGURE 5 | IMOD skews T helper cell polarization toward TH2.
Immature dendritic cells were incubated for 48 h with IMOD in the
presence (B) or absence (A) of LPS (10 ng/mL). Next naïve CD4+ T cells
were added and after 13 days of co-culture the differentiation was
assessed by staining for intracellular INF-γ (TH1) and IL4 (TH2) by flow
cytometry. The results represented as mean ± standard deviation of three
independent experiments. ∗P < 0.05; ∗∗P < 0.01. IMOD/LPS-treated vs.
LPS stimulated samples.
is further supported by the attenuation of T cell activation
by IMOD-treated DC. Thus, IMOD strongly counteracts pro-
inﬂammatory responses which might prevent immune-mediated
tissue damage.
IMOD skewed TH cell diﬀerentiation toward a TH2 response.
Although induction of TH2 responses is aﬀected by diﬀerent
cytokines and cell-surface molecules (Pulendran et al., 2010), our
data suggest that IMOD-mediated suppression of IL-12 might
underlie the observed TH2 polarization.
Although the mechanism of action is unclear, our data
strongly suggest that IMOD aﬀects TLR4 signaling and thereby
prevent pro-inﬂammatory cytokine induction. Interestingly,
components of IMOD have been shown to interact with the
C-type lectin DC-SIGN and might thereby aﬀect TLR signal-
ing as shown for mannose- and fucose-containing carbohydrate
structures (Gringhuis et al., 2014). Recently we have shown that
fucose binding to DC-SIGN leads to the activation of Bcl3, which
represses proinﬂammatory cytokine expression, while induc-
ing IL-10 and TH2-attracting chemokine expression, leading to
TH2 polarization (Gringhuis et al., 2014). Further research is
required to elucidate the signaling pathway induced by IMOD
that aﬀects TLR4 signaling. TLR-mediated immune responses
play an important role in a variety of diseases including infec-
tious diseases, autoimmune diseases, and atherosclerosis (Cook
et al., 2004). Therefore manipulation of TLR-triggered signaling
is of wide clinical interest and the IMOD-induced signaling path-
way might prove to be important in the development of novel
immunotherapies.
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